These results demonstrate that co-treatment with sunitinib can reverse the increase in CD11b+Gr1+ cells caused by agonistic anti-CD40 antibody treatment in the tumor draining lymph node, while the effect on tumor CD11b+Gr1+ MDSCs is dependent on the tumor model. This evidence concerns the gene ITGAM and neoplasm.